We are a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to trick the body s immune system to attack tumor cells by making…
Negative free cash flow of -$28M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$31M
▼ -38.6% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (TTM)
-$27M
▼ -87.4% YoY
Op. Cash Flow (TTM)
-$27M
▼ -87.6% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$6M
Continue Research